Neuroblastoma and treatment-related myelodysplasia/leukemia: The Memorial Sloan-Kettering experience and a literature review Review uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Leukemia, Myeloid
  • Myelodysplastic Syndromes
  • Neuroblastoma

abstract

  • Neuroblastoma itself is not associated with a host susceptibility to leukemia. However, current neuroblastoma treatment programs that use high-dose cyclophosphamide, cisplatin, and topoisomerase-II inhibitors may entail a considerable risk for t-AML. The incidence of t-AML in neuroblastoma patients may be underestimated because treatment and clinical factors can mask its presence. Efforts to devise effective but less leukemogenic treatment for neuroblastoma or to truncate leukemogenic therapy, eg, by exploiting molecular techniques for the early identification of complete remission, are warranted.

publication date

  • December 1998

Research

keywords

  • Review

Identity

Language

  • eng

PubMed ID

  • 9850034

Additional Document Info

start page

  • 3880

end page

  • 9

volume

  • 16

number

  • 12